Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs iShares MSCI India ETF (INDA) Price & Performance

AbCellera Biologics IncTrade
iShares MSCI India ETFTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs iShares MSCI India ETF — how do they compare? AbCellera Biologics Inc trades at $10.01 (market cap $2.99B), while iShares MSCI India ETF trades at $49.95. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.

ABCLINDA
Market Cap
$2.99B
Sector
HealthBroad Market / Factor
52-Week High
$9.76$55.29
52-Week Low
$2.78$45.42
Enterprise Value
$2.58B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.

The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.

iShares MSCI India ETF

INDA trades at $50.04, down 0.2% with a bullish technical signal from moving averages. The ETF reflects India's economic growth at 7.8% (CNBC, 2026-06-05) but faces headwinds from foreign outflows and sector-specific challenges in pharma and IT. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while ADX indicates strong trend strength.

Outlook remains cautiously optimistic given India's strong economic fundamentals, though near-term risks include geopolitical tensions, monsoon uncertainties, and foreign capital rotation away from emerging markets. The ETF offers exposure to the world's fastest-growing large economy but requires monitoring of external pressures.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About iShares MSCI India ETF

INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.

Read more on INDA